PERIDOT

Summary:

A randomized, double-blind, placebo-controlled, 12-month Phase III study to evaluate the the effect of an investigational oral study drug on neuropathic and abdominal pain in male and female adults with Fabry disease who are treatment-naive or untreated for at least 6 months.